TITLE

Prevention of Mother-To-Child Transmission of HIV: Cost-Effectiveness of Antiretroviral Regimens and Feeding Options in Rwanda

AUTHOR(S)
Binagwaho, Agnes; Pegurri, Elisabetta; Drobac, Peter C.; Mugwaneza, Placidie; Stulac, Sara N.; Wagner, Claire M.; Karema, Corine; Tsague, Landry
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Rwanda's National PMTCT program aims to achieve elimination of new HIV infections in children by 2015. In November 2010, Rwanda adopted the WHO 2010 ARV guidelines for PMTCT recommending Option B (HAART) for all HIV-positive pregnant women extended throughout breastfeeding and discontinued (short course-HAART) only for those not eligible for life treatment. The current study aims to assess the cost-effectiveness of this policy choice. Methods: Based on a cohort of HIV-infected pregnant women in Rwanda, we modelled the cost-effectiveness of six regimens: dual ARV prophylaxis with either 12 months breastfeeding or replacement feeding; short course HAART (Sc-HAART) prophylaxis with either 6 months breastfeeding, 12 months breastfeeding, or 18 months breastfeeding; and Sc-HAART prophylaxis with replacement feeding. Direct costs were modelled based on all inputs in each scenario and related unit costs. Effectiveness was evaluated by measuring HIV-free survival at 18 months. Savings correspond to the lifetime costs of HIV treatment and care avoided as a result of all vertical HIV infections averted. Results: All PMTCT scenarios considered are cost saving compared to “no intervention.” Sc-HAART with 12 months breastfeeding or 6 months breastfeeding dominate all other scenarios. Sc-HAART with 12 months breastfeeding allows for more children to be alive and HIV-uninfected by 18 months than Sc-HAART with 6 months breastfeeding for an incremental cost per child alive and uninfected of 11,882 USD. This conclusion is sensitive to changes in the relative risk of mortality by 18 months for exposed HIV-uninfected children on replacement feeding from birth and those who were breastfed for only 6 months compared to those breastfeeding for 12 months or more. Conclusion: Our findings support the earlier decision by Rwanda to adopt WHO Option B and could inform alternatives for breastfeeding duration. Local contexts and existing care delivery models should be part of national policy decisions.
ACCESSION #
87623454

 

Related Articles

  • Exclusive breastfeeding among women taking HAART for PMTCT of HIV-1 in the Kisumu Breastfeeding Study. Okanda, John O.; Borkowf, Craig B.; Girde, Sonali; Thomas, Timothy K.; Lee Lecher, Shirley // BMC Pediatrics;2014, Vol. 14 Issue 1, p1 

    Background One of the most effective ways to promote the prevention of mother-to-child transmission (PMTCT) of HIV-1 in resource-limited settings is to encourage HIV-positive mothers to practice exclusive breastfeeding (EBF) for the first 6 months post-partum while they receive antiretroviral...

  • Consultation on HIV transmission and breast-feeding.  // Women's International Network News;Spring93, Vol. 19 Issue 2, p42 

    Presents excerpts of a joint statement by the World Health Organization and the United Nations International Children's Emergency Fund on the increasing concern of HIV transmission through breastfeeding. Aim of the consultation on HIV transmission between the two organizations; Benefits of...

  • WHO 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe: Modeling Clinical Outcomes in Infants and Mothers. Ciaranello, Andrea L.; Perez, Freddy; Maruva, Matthews; Chu, Jennifer; Engelsmann, Barbara; Keatinge, Jo; Walensky, Rochelle P.; Mushavi, Angela; Mugwagwa, Rumbidzai; Dabis, Francois; Freedberg, Kenneth A. // PLoS ONE;2011, Vol. 6 Issue 6, p1 

    Background: The Zimbabwean national prevention of mother-to-child HIV transmission (PMTCT) program provided primarily single-dose nevirapine (sdNVP) from 2002-2009 and is currently replacing sdNVP with more effective antiretroviral (ARV) regimens. Methods: Published HIV and PMTCT models, with...

  • Health Outcomes and Cost Impact of the New WHO 2013 Guidelines on Prevention of Mother-to-Child Transmission of HIV in Zambia. Ishikawa, Naoko; Shimbo, Takuro; Miyano, Shinsuke; Sikazwe, Izukanji; Mwango, Albert; Ghidinelli, Massimo N.; Syakantu, Gardner // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Background: Countries are currently progressing towards the elimination of new paediatric HIV infections by 2015. WHO published new consolidated guidelines in June 2013, which now recommend either ‘Antiretroviral drugs (ARVs) for women living with HIV during pregnancy and breastfeeding...

  • Three out of four WHO HIV options pass muster.  // PharmacoEconomics & Outcomes News;1/22/2011, Issue 620, p5 

    The article discusses research on the cost-effectiveness of antiretroviral regimens in the World Health Organization treatment guidelines, referencing a study by E. Bendavid and colleagues published in the November 30, 2010 issue of "AIDS."

  • Transmitted Antiretroviral Drug Resistance Among Drug-Naive Female Sex Workers With Recent Infection in Kampala, Uganda. Ssemwanga, Deogratius; Ndembi, Nicaise; Lyagoba, Frederick; Magambo, Brian; Kapaata, Anne; Bukenya, Justine; Lubega, George W.; Bertagnolio, Silvia; Vandepitte, Judith; Grosskurth, Heiner; Kaleebu, Pontiano // Clinical Infectious Diseases;May2012 Supplement 4, Vol. 54 Issue suppl_4, pS339 

    During 2006–2007, transmitted human immunodeficiency virus (HIV) drug resistance (TDR) among drug-naive women with newly diagnosed HIV infection and likely to be recently infected when attending antenatal clinics in Entebbe was found to be <5% with use of the World Health Organization...

  • World Health Organization sets out route map for scale-up of treatment as prevention. Alcorn, Keith // CME: Continuing Medical Education;Jul2012, Vol. 30 Issue 7, p265 

    The article reports that Doctor Gottfied Hirnschall, the head of the World Health Organization's HIV department announced during the International Association Physicians in AIDS Care (IAPAC) summit in London, England that people on antiretroviral treatment (ART) will rise to about 6 million...

  • The Strategic Use of Antiretrovirals to Prevent HIV Infection: A Converging Agenda. Baggaley, Rachel; Doherty, Meg; Ball, Andrew; Ford, Nathan; Hirnschall, Gottfried // Clinical Infectious Diseases;2015 Supplement, Vol. 60, pS159 

    There is a clear convergence toward an overarching strategic use of antiretroviral drugs to prevent human immunodeficiency virus (HIV) infection. Four interventions-immediate antiretroviral therapy (ART) for the infected partner in a serodiscordant couple, preexposure prophylaxis (PrEP),...

  • Antiretroviral Therapy and Reasons for Not Taking It among Men Having Sex with Men (MSM)—Results from the European MSM Internet Survey (EMIS). Marcus, Ulrich; Hickson, Ford; Weatherburn, Peter; Furegato, Martina; Breveglieri, Michele; Berg, Rigmor C.; Schmidt, Axel J.; null, null // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Background: The preventive effects of antiretroviral treatment (ART) on onward transmission of HIV are a major reason for broadening eligibility for ART. In the WHO European Region, surveillance reveals substantial differences in access to ART across regions and sub-populations. We analysed...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics